** Shares of drug distributor Cencora COR.N rise 1.7% to $255.77
** Co raises fiscal 2025 profit forecast, driven by robust demand for expensive specialty medicines
** Expects 2025 adj. profit to range between $15.25 and $15.55 per share, up from previous view of $15.15 to $15.45
** Reports adj. Q1 profit of 3.73 per share, beating estimates of $3.50 per share - data compiled by LSEG
** Q1 sales in its U.S. healthcare solutions segment rose 13.6% to $74.0 billion
** "COR is off to a strong year stock-wise, but we see this quarter/guidance as another reason to see further upside on both estimates and multiple expansion," brokerage Leerink Partners says
** Stock rose 9.4% in 2024
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。